Background Breast cancer (BC) is one of the solid tumors most commonly associated with
leptomeningeal disease (LMD). LMD carries a devastating prognosis; however, disease …

Background Disease presentation, prognostic factors, and treatment patterns for patients
with breast cancer with leptomeningeal metastasis are not well characterized. In this study …

2070 Background: Around 5% of patients with breast cancers (BC) will develop
leptomeningeal metastasis (LM). The incidence may increase. Methods: We reported the …

Background There is limited data on the impact of specific patient characteristics, tumor
subtypes or treatment interventions on survival in breast cancer LM. Methods A systematic …

Background Leptomeningeal metastasis (LM) is one of the major problems in the
management of metastatic breast cancer; typically, LM has a devastating prognosis and …

The study aimed to assess factors affecting survival of breast cancer patients suffering
leptomeningeal metastasis (LM) and to compare survivals in patients with LM as the first and …

Background Breast cancer-related leptomeningeal disease (BC-LMD) is a dire diagnosis for
5–8% of patients with breast cancer (BC). We conducted a retrospective review of BC-LMD …

Leptomeningeal metastasis (LM) usually occurs late during the course of breast cancer. The
aim of this study was to characterize the clinical features and outcomes of LM based on …

In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer,
leptomeningeal metastases (LM) are a rare but often a fatal clinical scenario. In this …

Introduction Metastatic breast cancer (MBC) with leptomeningeal metastases (LM) has
dismal survival. We aim to determine if modern systemic therapy, especially the …